<DOC>
	<DOCNO>NCT02817347</DOCNO>
	<brief_summary>In patient otitis medium present otoscopy-confirmed otorrhea tympanostomy tube insertion tympanic perforation , evaluate safety , tolerability , proportion patient cessation otorrhea ear-drop administration YH1177 YH1177-D 14 day therefore determine optimal clinical dose .</brief_summary>
	<brief_title>A Clinical Trial YH1177 Patients With Otitis Media Otorrhea</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<criteria>Signed Written Informed Consent A detailed explanation study , include study purpose procedure drug property , provide , patient give voluntary write informed consent . Target Population Patients otitis medium present otorrhea , evidence otoscopy , tympanostomy tube insertion tympanic perforation Sex age Male female patient 19 year age old screen Women childbearing potential ( WOCBP ) must 'negative ' pregnancy test screening , use acceptable method contraception throughout study . Excluded Disease 1 . Patients diagnose otitis medium cholesteatoma , otitis medium effusion otitis externa screen 2 . Patients otologic surgery within 1 year prior screening ( except tympanostomy tube insertion ) 3 . Subjects previously cholesteatoma mastoid surgery Medical History Concurrent Disease 1 . Patients complication labyrinthine fistula screen 2 . Patients clinically significant medical mental illness . 3 . Patients infectious disease require use systemic antimicrobial therapy Physical Laboratory Test Results ) Clinically significant finding base principal investigator/investigator 's opinion . Allergies Adverse Drug Reactions 1 . Known drug allergy ( e.g. , history anaphylaxis hepatotoxicity ) 2 . History hypersensitivity penicillins lactamase inhibitor . 3 . History serious skin reaction StevensJohnson syndrome toxic epidermal necrosis Prohibited Therapies and/or Medication 1 . Patients undergo ventilation tube insertion day screen 2 . Patients ventilation tube contain silver oxide silver salt ( e.g. , Ttype tube ) Reproductive status , Women ) Woman childbearing potential ( WOCBP ) unable , unwilling use acceptable method contraception study Other Exclusion Criteria 1 . History alcohol drug abuse/addiction within last 1 year prior study entry 2 . Patient , investigator 's opinion , suitable study reason ( e.g. , ECG hepatitis test result screen )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>